Menlo Therapeutics Stock Price, News & Analysis (NASDAQ:MNLO)

$33.96 -0.92 (-2.64 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$33.96
Today's Range$33.47 - $35.68
52-Week Range$20.50 - $39.86
Volume62,200 shs
Average Volume192,094 shs
Market Capitalization$764.85 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Menlo Therapeutics (NASDAQ:MNLO)

Menlo Therapeutics logoMenlo Therapeutics Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The Company offers VPD-737 (serlopitant), a potent oral NK1 receptor antagonist for the treatment of severe, chronic pruritus associated with or without a diagnosed disease. The Company studies VPD-737 in a randomized, double blind, placebo controlled study over eight weeks to assess the safety and efficacy of VPD-737 in patients with prurigo nodularis. The Company has conducted Phase II study evaluating the investigational oral NK-1 receptor antagonist VPD-737 (serlopitant) for the treatment of patients with severe, chronic itch who are unresponsive or inadequately responsive to the standard of care, including topical steroids and antihistamines.

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNLO
CUSIPN/A
WebN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares21,930,000

Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

Where is Menlo Therapeutics' stock going? Where will Menlo Therapeutics' stock price be in 2018?

4 Wall Street analysts have issued 1-year price objectives for Menlo Therapeutics' stock. Their predictions range from $41.00 to $52.00. On average, they anticipate Menlo Therapeutics' share price to reach $46.25 in the next twelve months. View Analyst Ratings for Menlo Therapeutics.

Who are some of Menlo Therapeutics' key competitors?

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the folowing people:

  • Steven L. Basta, Chief Executive Officer, Director (Age 50)
  • Danine Summers, Senior Vice President - Medical Affairs
  • Xiaoming Zhang Ph.D., Senior Vice President - Non-Clinical and CMC
  • Paul S. Kwon M.D., Chief Medical Officer
  • David J. Collier M.D., Director (Age 51)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an IPO on Thursday, January 25th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and JMP Securities was co-manager.

When does the company's quiet period expire?

Menlo Therapeutics' quiet period expires on Tuesday, March 6th. Menlo Therapeutics had issued 7,000,000 shares in its public offering on January 25th. The total size of the offering was $119,000,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Who owns Menlo Therapeutics stock?

Menlo Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (5.10%). View Institutional Ownership Trends for Menlo Therapeutics.

How do I buy Menlo Therapeutics stock?

Shares of Menlo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of Menlo Therapeutics stock can currently be purchased for approximately $33.96.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $764.85 million.


MarketBeat Community Rating for Menlo Therapeutics (MNLO)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  10
MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Menlo Therapeutics (NASDAQ:MNLO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyN/AN/AN/A
Consensus Rating Score: 3.00N/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $46.25N/AN/AN/A
Price Target Upside: 32.60% upsideN/AN/AN/A

Menlo Therapeutics (NASDAQ:MNLO) Consensus Price Target History

Price Target History for Menlo Therapeutics (NASDAQ:MNLO)

Menlo Therapeutics (NASDAQ:MNLO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2018JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$44.00 -> $44.00HighView Rating Details
2/20/2018Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$48.00HighView Rating Details
2/20/2018Jefferies GroupInitiated CoverageBuy -> Buy$41.00HighView Rating Details
2/19/2018GuggenheimInitiated CoverageBuy -> Buy$52.00HighView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Earnings History for Menlo Therapeutics (NASDAQ:MNLO)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Menlo Therapeutics (NASDAQ:MNLO) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Menlo Therapeutics (NASDAQ:MNLO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Menlo Therapeutics (NASDAQ MNLO) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Menlo Therapeutics (NASDAQ:MNLO)

Menlo Therapeutics (NASDAQ MNLO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/25/2018Vivo Capital Surplus Fund ViiiMajor ShareholderBuy294,118$17.00$5,000,006.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Menlo Therapeutics (NASDAQ MNLO) News Headlines

Source:
DateHeadline
Zacks: Menlo Therapeutics Inc (MNLO) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: Menlo Therapeutics Inc (MNLO) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - February 21 at 9:52 AM
Jefferies Group Initiates Coverage on Menlo Therapeutics (MNLO)Jefferies Group Initiates Coverage on Menlo Therapeutics (MNLO)
www.americanbankingnews.com - February 20 at 10:40 PM
Piper Jaffray Companies Begins Coverage on Menlo Therapeutics (MNLO)Piper Jaffray Companies Begins Coverage on Menlo Therapeutics (MNLO)
www.americanbankingnews.com - February 20 at 9:30 PM
JMP Securities Begins Coverage on Menlo Therapeutics (MNLO)JMP Securities Begins Coverage on Menlo Therapeutics (MNLO)
www.americanbankingnews.com - February 20 at 6:48 PM
Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of DermatologyMenlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology
finance.yahoo.com - February 20 at 3:17 PM
Menlo Therapeutics (MNLO) Coverage Initiated at GuggenheimMenlo Therapeutics (MNLO) Coverage Initiated at Guggenheim
www.americanbankingnews.com - February 19 at 4:12 PM
BRIEF-Novo Holdings Reports 5.05 Pct Passive Stake In Menlo TherapeuticsBRIEF-Novo Holdings Reports 5.05 Pct Passive Stake In Menlo Therapeutics
www.reuters.com - February 9 at 8:01 AM
Palo Alto creator of software for CFOs may be ready to go public this yearPalo Alto creator of software for CFOs may be ready to go public this year
finance.yahoo.com - February 1 at 5:28 PM
[$$] Biotechs Brisk March Into Public Markets[$$] Biotech's Brisk March Into Public Markets
finance.yahoo.com - January 31 at 1:12 PM
Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMenlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 31 at 1:12 PM
Nasdaq Exec Even More Bullish On Biotech IPOs As New Entries SoarNasdaq Exec 'Even More Bullish' On Biotech IPOs As New Entries Soar
finance.yahoo.com - January 31 at 1:12 PM
Insider Buying: Menlo Therapeutics Inc (MNLO) Major Shareholder Purchases 294,118 Shares of StockInsider Buying: Menlo Therapeutics Inc (MNLO) Major Shareholder Purchases 294,118 Shares of Stock
www.americanbankingnews.com - January 29 at 6:14 PM
Menlo Therapeutics Closes in on IPOMenlo Therapeutics Closes in on IPO
247wallst.com - January 19 at 7:30 PM
Menlo Therapeutics Files For $85 Million IPO - Seeking AlphaMenlo Therapeutics Files For $85 Million IPO - Seeking Alpha
seekingalpha.com - January 18 at 8:02 AM
Menlo Therapeutics Plans $86 Million IPO for January 25th (MNLO)Menlo Therapeutics Plans $86 Million IPO for January 25th (MNLO)
www.americanbankingnews.com - January 13 at 1:04 AM

SEC Filings

Menlo Therapeutics (NASDAQ:MNLO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Menlo Therapeutics (NASDAQ MNLO) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.